Condition
Late-Onset Asthma
Total Trials
3
Recruiting
0
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Completed1
Active Not Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04612556Active Not Recruiting
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
NCT03747211Not ApplicableTerminatedPrimary
Asthma Severity in Women: The Influence of Training and Menopause
NCT03278561Completed
General Risk Factors and Inflammatory Determinants in Older Patients With Asthma
Showing all 3 trials